Mr. Egge brings over 25 years of
biopharmaceutical experience building commercial organizations and
successfully launching novel therapeutic products
INOVIO poised to become a commercial-stage
company with plans to submit a Biologics License Application for
INO-3107 in second half of 2024 under U.S. Food and Drug
Administration's Accelerated Approval Pathway
PLYMOUTH
MEETING, Pa., July 2, 2024
/PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company
focused on developing and commercializing DNA medicines to help
treat and protect people from HPV-related diseases, cancer, and
infectious diseases, today announced the appointment of
Steven Egge as Chief Commercial
Officer. Mr. Egge will lead the company's commercial strategy and
operations as it prepares to potentially launch its first DNA
medicine product, INO-3107 as a treatment for recurrent respiratory
papillomatosis (RRP).
"We are delighted to welcome Steve to INOVIO and look forward to
adding his expertise to our leadership team as we continue
advancing our preparations to commercially launch INO-3107 in 2025,
should it receive approval by the FDA as a treatment for RRP," said
Dr. Jacqueline Shea, INOVIO's
President and Chief Executive Officer. "Steve joins us at an
exciting time, as we prepare to become a commercial-stage company,
while advancing multiple product candidates targeting unmet medical
needs. His expertise launching new products, driving market share
in competitive environments, and growing overall therapeutic areas
will be advantageous to the development and implementation of our
commercial plans, as will his experience across immunology and
vaccines, HPV, and rare diseases."
"This is a great time to join INOVIO as the company has the
opportunity to market the first therapeutic option for patients
suffering from RRP, a rare and debilitating HPV-related disease
that significantly impacts quality of life," said Mr. Egge. "I look
forward to working with the talented team at INOVIO and continuing
the ongoing efforts to build out the company's commercial
strategies and capabilities."
Mr. Egge comes to INOVIO from Sumitomo Pharma (formerly Myovant
Sciences, acquired by Sumitovant Biopharma, a subsidiary of
Sumitomo Pharma, in 2023), where as Senior Vice President and
General Manager for Women's Health he was responsible for building
the commercial leadership team, accelerating the launch of
Myfembree® and helping lead the company's expansion into new
indications. Mr. Egge was at Merck for twenty years, where he held
a number of senior commercial leadership roles, including leading
Merck's HPV Vaccines Franchise as well as Chief Marketing Officer
for the Vaccine Division, where he oversaw launches for new
indications for GARDASIL®, a re-launch of ZOSTAVAX®, and launch
planning for GARDASIL9® and VAXELIS®. Mr. Egge also served as
Global Commercial Head for Merck's Fertility Franchise, where he
oversaw the launch of ELONVA® in ex-U.S. markets. After Merck, Mr.
Egge served as Senior Vice President at Genfit Corp., a French
biotech company focused on liver diseases, where he led commercial
planning and business development.
About INOVIO's DNA Medicines Platform
INOVIO's DNA
medicines platform has two innovative components: precisely
designed DNA plasmids, delivered by INOVIO's proprietary
investigational medical device, CELLECTRA®. INOVIO uses proprietary
technology to design its DNA plasmids, which are small circular DNA
molecules that work like software the body's cells can download to
produce specific proteins to target and fight disease. INOVIO's
proprietary CELLECTRA® delivery devices are designed to optimally
deliver its DNA medicines to the body's cells without requiring
chemical adjuvants or lipid nanoparticles and without the risk of
the anti-vector response historically seen with viral vector
platforms.
About INOVIO
INOVIO is a biotechnology company focused
on developing and commercializing DNA medicines to help treat and
protect people from HPV-related diseases, cancer, and infectious
diseases. INOVIO's technology optimizes the design and delivery of
innovative DNA medicines that teach the body to manufacture its own
disease-fighting tools. For more information, visit
www.inovio.com.
CELLECTRA® is a trademark of
INOVIO.
GARDASIL®,
GARDASIL9®, ZOSTAVAX® and
ELONVA® are trademarks of Merck and Co.,
Inc.
VAXELIS® is trademark of The MSP
Vaccine Company.
Myfembree® is
trademark of Sumitomo Pharma Switzerland GmbH.
Forward-Looking Statements
This press release contains
certain forward-looking statements relating to our business,
including our plans to develop and commercialize DNA medicines and
expectations regarding our research and development programs,
including the planned submission of a BLA in the second half of
2024 and the planned commercial launch of INO-3107 if regulatory
approval is obtained. Actual events or results may differ from the
expectations set forth herein as a result of a number of factors,
including uncertainties inherent in pre-clinical studies, clinical
trials, product development programs and commercialization
activities and outcomes, the availability of funding to support
continuing research and studies in an effort to prove safety and
efficacy of electroporation technology as a delivery mechanism or
develop viable DNA medicines, our ability to support our pipeline
of DNA medicine products, the ability of our collaborators to
attain development and commercial milestones for products we
license and product sales that will enable us to receive future
payments and royalties, the adequacy of our capital resources, the
availability or potential availability of alternative therapies or
treatments for the conditions targeted by us or collaborators,
including alternatives that may be more efficacious or cost
effective than any therapy or treatment that we and our
collaborators hope to develop, issues involving product liability,
issues involving patents and whether they or licenses to them will
provide us with meaningful protection from others using the covered
technologies, whether such proprietary rights are enforceable or
defensible or infringe or allegedly infringe on rights
of others or can withstand claims of invalidity and whether we can
finance or devote other significant resources that may be necessary
to prosecute, protect or defend them, the level of corporate
expenditures, assessments of our technology by potential corporate
or other partners or collaborators, capital market conditions, the
impact of government healthcare proposals and other factors set
forth in our Annual Report on Form 10-K for the year ended
December 31, 2023, our Quarterly
Report on Form 10-Q for the quarter ended March 31, 2024, and other filings we make from
time to time with the Securities and Exchange Commission. There can
be no assurance that any product candidate in our pipeline will be
successfully developed, manufactured, or commercialized, that the
results of clinical trials will be supportive of regulatory
approvals required to market products, or that any of the
forward-looking information provided herein will be proven
accurate. Forward-looking statements speak only as of the date of
this release, and we undertake no obligation to update or revise
these statements, except as may be required by law.
Contacts
Media: Jennie
Willson (267) 429-8567 jennie.willson@inovio.com
Investors: Thomas Hong (267)
440-4298 thomas.hong@inovio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/inovio-announces-appointment-of-steven-egge-as-chief-commercial-officer-302188348.html
SOURCE INOVIO Pharmaceuticals, Inc.
